PAIN ASPIRINE AND INFLAMMATION 500 MG
Analgesics and antipyretics.
Tablet core: colloidal silicon dioxide; anhydrous sodium carbonate. Coating: carnauba wax; hypromellose; zinc stearate.
Symptomatic treatment of fever and / or mild to moderate pain, such as headache, flu syndrome, toothache, muscle pain.
CONTRAINDICATIONS / EFF.SECONDAR
Hypersensitivity 'to acetylsalicylic acid or to other salicylates, or to any of the excipients; history of asthma or hypersensitivity reactions (e.g. urticaria, angioedema, severe rhinitis, shock) induced by the administration of salicylates or substances with a similar action, in particular non-steroidal anti-inflammatory drugs (NSAIDs); active ulcerapeptic; hemorrhagic diathesis; severe kidney failure; severe liver failure; uncontrolled severe heart failure; concomitant administration of methotrexate in doses above 20 mg per week, for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses; concomitant administration of oral anticoagulants for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses and in patients with a history of gastroduodenal ulcers; since the beginning of the sixth month of pregnancy (beyond the twenty-fourth week of amenorrhea); children and boys under 16 years of age.
Adults and children (from 16 years onwards): 1 to 2 tablets for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose must not exceed 6 tablets. Elderly (from 65 years): 1 tablet for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose must not exceed 4 tablets. Acetylsalicylic acid should not be taken for more than 3 days (in case of fever) or 3 - 4 days (in case of pain) unless otherwise indicated by the doctor. Pediatric population: acetylsalicylic acid should not be used in children and young people under the age of 16 without a prescription. Acetylsalicylic acid should be used with caution in patients with abnormal liver or kidney function or with circulatory problems. Method of administration: for oral use. The tablets should be taken with an adequate quantity of liquids.
Do not store above 30 degrees C.
In case of combination with other medicinal products, to avoid any risk of overdose, check that acetylsalicylic acid is absent from the composition of these other medicines. Reye's syndrome, a very rare and potentially life-threatening disease, has been described in children with symptoms of viral infections (especially chicken pox and flu episodes) with or without taking acetylsalicylic acid. Consequently, acetylsalicylic acid should only be given to children in these conditions after medical advice and when other measures have proven ineffective. If persistent vomiting occurs, changes in your state of consciousness or abnormal behavior, treatment with acetylsalicylic acid should be stopped. In case of prolonged administration of high-dose analgesic, the attack of headache should not be treated with higher doses. The regular use of analgesics, in particular a combination of analgesics, can lead to permanent kidney injury, with the risk of kidney failure. In some severe forms of G6PD deficiency, high doses of acetylsalicylic acid can cause hemolysis. In case of G6PD deficiency, acetylsalicylic acid should be administered under medical supervision. Monitoring of treatment should be intensified in the following cases: in patients with a history of gastric or duodenal ulcer, gastrointestinal bleeding, or gastritis; in patients with renal insufficiency; in patients with liver failure; in patients with asthma: the occurrence of a diasma attack, in some patients, can be linked to an allergy to nonsteroidal anti-inflammatory drugs or to acetylsalicylic acid; in this case, this medicine is contraindicated; in patients with metrorrhagia or menorrhagia (risk of increased volume and cycle duration). Gastrointestinal bleeding or ulcers / perforations can occur at any time during treatment, without there being necessarily any warning signs or medical history in the patient. The relative risk increases in elderly subjects, in subjects with reduced body weight, and in patients receiving anticoagulants or platelet aggregation inhibitors. In case of gastrointestinal bleeding, treatment should be stopped immediately. Given the inhibitory effect of acetylsalicylic acid on platelet aggregation, which occurs even at very low doses and persists for several days, the patient should be aware of the risk of bleeding in the event of surgery, even of a small entity (e.g. . dental extraction). In analgesic or antipyretic doses, acetylsalicylic acid inhibits the excretion of uric acid; in the doses used in rheumatology (anti-inflammatory doses), acetylsalicylic acid has a uricosuric effect. The use of this medicine is not recommended during breastfeeding. The administration of acetylsalicylic acid is not recommended with: oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid (> = 500 mg per administration and / or <3 g per day) and in patients without a history of gastro-duodenal ulcers. Other non-steroidal anti-inflammatory anti-inflammatory drugs (NSAIDs) of acetylsalicylic acid (> = 1 g per administration and / or> = 3 g per day) or with doses of analgesic or antipyretic acetylsalicylic acid (> = 500 mg for administration and / or <3 day). Low molecular weight heparins (and related molecules) and unfractionated heparins with therapeutic doses or in elderly patients (> 65 years old) regardless of the dose of heparin, and for anti-inflammatory doses of acetylsalicylic acid (> = 1g per administration and / or> = 3g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (> = 500 mg per administration and / or <3 g per day); clopidogrel (beyond the indications approved for this association in patients with acute coronary artery disease); ticlopidine; uricosuric; glucocorticoids (with the exception of replacement therapy with hydrocortisone) for doses of anti-inflammatory acetylsalicylic acid (> = 1 g per administration and / or> = 3 g per day); pemetrexed in patients with mild to moderate reduced renal function (creatinine clearance between 45 ml / min and 80 ml / min); anagrelide: increased risk of bleeding and decreased antithrombotic effect.
In the following text, the following definitions apply: anti-inflammatory doses of acetylsalicylic acid are defined as "> = 1g per administration and / or> = 3g per day"; analgesic or antipyretic doses of acetylsalicylic acid are defined as "> = 500 mg per administration and / or <3 g per day". Different substances give rise to interactions, due to their properties of platelet aggregation inhibitors: abciximab, acetylsalicylic acid, cilostazol, clopidogrel, epoprostenol, eptifibatide, iloprost, iloprost trometamol, prasugrel, ticlopidine, tirofiban, ticagrelor. The risk of bleeding increases with the use of multiple platelet aggregation inhibitors as well as with their use in combination with heparin or related molecules, oral anticoagulants or other thrombolytics, and must be evaluated through constant clinical monitoring. >> Contraindicated combinations. Methotrexate in doses above 20 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular of haematological toxicity (due to the reduced renal elimination of methotrexate caused by acetylsalicylic acid). Oral anticoagulants with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid and in patients with a history of gastroduodenal ulcers: increased risk of bleeding. >> Combinations not recommended. Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid and in patients without a history of gastroduodenal ulcers: increased risk of bleeding. Other nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and bleeding. Low molecular weight heparins (related hemolecules) and unfractionated heparins at curative doses, or in elderly patients (> = 65 years) regardless of the dose of heparin, and for anti-inflammatory doses of acetylsalicylic acid or analgesic or antipyretic doses of acetylsalicylic acid: increased risk of hemorrhage (inhibition of platelet aggregation and aggression of the gastroduodenal mucosa by acetylsalicylic acid). Another anti-inflammatory drug, or another analgesic or antipyretic should be used. Clopidogrel (outside the indication approved for this combination in patients with acute coronary syndrome): increased risk of bleeding. If concomitant administration cannot be avoided, clinical monitoring is recommended. Ticlopidine: increased risk of bleeding. If concomitant administration cannot be avoided, clinical monitoring is recommended. Uricosurics (benzbromarone, probenecid): reduction of the uricosuric effect due to competition for the elimination of uric diacid in the renal tubules. Glucocorticoids (excluding replacement therapy with hydrocortisone) for anti-inflammatory doses of acetylsalicylic acid: increased risk of bleeding. Pemetrexed in patients with mild to moderate renal impairment (creatinine clearance between 45 ml / min and 80 ml / min); increased risk of pemetrexed ditoxicity (due to decreased dipemetrexed renal elimination caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Anagrelide: increased risk of bleeding and decreased antithrombotic effect. If concomitant administration cannot be avoided, clinical monitoring is recommended. >> Combinations requiring precautions for use. Diuretics, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, with anti-inflammatory doses of acetylsalicylic acid or with analgesic or antipyretic doses of acetylsalicylic acid: acute renal failure may occur in dehydrated patients by the reduction of the glomerular filtration rate due to the decreased renal prostaglandin synthesis. In addition, there may be a reduction in the antihypertensive effect. Make sure the patient is hydrated and that kidney function is monitored at the start of treatment. Methotrexate in doses <= 20 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular of haematological toxicity (due to the reduced renal elimination of methotrexate caused by 'acetylsalicylic acid). CBC should be monitored weekly during the first few weeks of concomitant administration. Patients with reduced (even mild) renal function and elderly patients should be closely monitored. Clopidogrel (in the indication approved for this combination in patients with acute coronary syndrome): increased risk of bleeding. Clinical monitoring is recommended. Topical gastrointestinal treatments, active ecarbone antacids: increased renal excretion of acetylsalicylic acid due to alkalinization of the urine. It is recommended to administer antacids and topical gastrointestinal treatments at least two hours after taking acetylsalicylic acid. Pemetrexed in patients with normal renal function: increased risk of toxicity from pemetrexed (due to the decrease in renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Kidney function should be monitored. >> Combinations that must be taken into consideration. Glucocorticoids (excluding replacement therapy with hydrocortisone) for analgesic and antipyretic doses of acetylsalicylic acid: increased risk of bleeding. Deferasirox: with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and hemorrhage. Low molecular weight heparins (and related molecules) and unfractionated heparins in preventive doses in patients <65 years of age 'diet: by influencing hemostasis at various levels, concomitant administration increases the risk of bleeding. Therefore, in such patients, the co-administration of heparins (or related molecules) in preventive doses, and acetylsalicylic acid in any dose, should be taken into consideration by combining it with clinical and laboratory monitoring as needed. Thrombolytics: increased risk of bleeding. Selective Serotonin Reuptake Inhibitors: increased risk of bleeding.
Frequencies: not known (cannot be estimated from the available data). Blood and lymphatic system disorders: bleeding and bleeding tendency (nosebleeds, bleeding gums, purpura, etc.) with increased bleeding time. The risk of bleeding may persist for 4-8 days after stopping acetylsalicylic acid. It can cause an increased risk of bleeding in case of surgery. Intracranial and gastrointestinal bleeding may also occur. Immune system disorders: hypersensitivity reactions, anaphylactic reactions, asthma, angioedema. Nervous system disorders: headache, dizziness, loss of hearing sensation, tinnitus, which usually indicate an overdose. Intracranial hemorrhage. Gastrointestinal disorders: abdominal pain. Gastrointestinal bleeding occult or full-blown (hematemesis, melena, etc.) with consequent iron deficiency anemia. The risk of bleeding is related to the dose. Gastric ulcers and perforations. Hepatobiliary disorders: elevation of liver enzymes usually reversible upon discontinuation of treatment, liver damage, mainly hepatocellular in nature. Skin and subcutaneous tissue disorders: urticaria, rash General disorders Reye's syndrome It is important to report the side effects of the medicine after authorization. This allows you to continue monitoring the risk-benefit balance of the medicine.
PREGNANCY AND BREASTFEEDING
Inhibition of prostaglandin synthesis can have adverse effects on the course of pregnancy and / or embryo-fetal development. Data from epidemiological studies suggest an increased risk of spontaneous abortion, heart malformations and gastroschisis following the use of inhibitors of prostaglandin synthesis in the early stages of pregnancy. The risk appears to increase with the dose and duration of treatment. In animals, it has been shown that the administration of a prostaglandin synthesis inhibitor causes an increase in pre and post implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which a prostaglandin synthesis inhibitor was administered during the organogenetic period of gestation. Unless absolutely essential, acetylsalicylic acid should not be administered during the first 24 weeks of amenorrhea. If acetylsalicylic acid is administered to women who wish to become pregnant or are pregnant during the first 24 weeks of amenorrhea, the dose should be as low as possible and the duration of treatment as short as possible. After the 24th week of amenorrhea, all inhibitors of prostaglandin synthesis can expose the fetus to: cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); kidney dysfunction, which can develop into kidney failure with oligohydroamniosis; In the final phase of pregnancy, the mother and the newborn can undergo: prolongation of the bleeding time, due to the inhibition of platelet aggregation which can also occur at very low doses of acetylsalicylic acid; inhibition of uterine contractions which causes labor delay or protraction. Therefore acetylsalicylic acid is contraindicated after the fifth month of pregnancy (over 24 weeks of amenorrhea). Acetylsalicylic acid passes into breast milk: therefore the use of acetylsalicylic acid is not recommended during breastfeeding. There is some evidence that drugs that inhibit cyclooxygenase / prostaglandin synthesis can cause impaired female fertility due to an effect on ovulation. This effect is reversible upon discontinuation of treatment.
Delivery is made within 24-72 working hours, Monday to Friday, excluding holidays.
WARNING! In times of high turnout, such as Black Friday, Christmas or Sales, delivery times may increase.
Shipping costs are calculated automatically during the order phase.
- EXPRESS shipping 24-72 working hours
For orders over € 40,00 shipping is free. For orders less than € 40,00 the following applies:
- - € 0,00 - € 9,99: € 6,99
- - € 10,00 - € 19,99: € 5,99
- - € 20,00 - € 29,99: € 4,99
- - € 30,00 - € 39,99: € 3,99
- - € 40,00 and up: € 0,00
- Cash on delivery
For orders over € 70,00 shipping is € 3.99. For orders less than € 70,00 the following applies:
- - € 0,00 - € 9,99: € 10,98
- - € 10,00 - € 19,99: € 9,98
- - € 20,00 - € 29,99: € 8,98
- - € 30,00 - € 39,99: € 7,98
- - € 40,00 - € 49,99: € 6,98
- - € 50,00 - € 59,99: € 5,98
- - € 60,00 - € 69,99: € 4,98
- - € 70,00 and up: € 3,99
WARNING! If you want to pay cash on delivery, when ordering you need to select the item twice, otherwise the total amount will be added € 3,99 for the service.
- Delivery by 12.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 12.00 on the following day, excluding Saturday and Sunday.
- € 10.99
- Delivery by 10.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 10.00 on the following day, excluding Saturday and Sunday.
- € 15.99
- € 7.98
Farmaveloce will deliver your order to the address of your choice throughout Italy, including the islands.
All orders with EXPRESS Shipping are entrusted to the Courier BRT, GLS, UPS, DHL, FedEx & TNT, Poste Italiane.
farmaveloce.com collects some Personal Data from its Users.
Owner of the Data Privacy
Via Savelli, 10 35129 Padua (Italy)
Email address of the owner: ROAD@ farmaveloce.com
The site: farmaveloce.com
Types of data collected
Among the Personal Data collected, independently or through third parties, there are: Cookies, Data of
use, name, surname, telephone number, VAT number, address, country, postcode, various types
of data, city and tax code.
Full details on each type of data collected are provided in the dedicated sections of this
Personal Data can be freely provided by the User or, in the case of Usage Data,
collected automatically when using the site.
Unless otherwise specified, all data requested by the site are mandatory.
If the User refuses to communicate them, it may be impossible for farmaveloce.com to provide the Service.
In cases where farmaveloce.com indicates some Data as optional, Users are free to
refrain from communicating such Data, without this having any consequence on the availability of the
Service or its operation.
Users who have doubts about which data are mandatory are encouraged to contact
of third party services used by the site, unless otherwise specified, has the purpose of providing the Service
requested by the User, in addition to the additional purposes described in this document and in the Cookie
Policy, if available.
The User assumes responsibility for the Personal Data of third parties obtained, published or shared
through farmaveloce.com and guarantees to have the right to communicate or disseminate them, freeing
the Owner from any liability to third parties.
Mode and place of processing of data collected
Mode of treatment
The Data Controller adopts the appropriate security measures to prevent access, disclosure, the
unauthorized modification or destruction of Personal Data.
The treatment is carried out using IT and / or telematic tools, with methods
organizational and with logic strictly related to the purposes indicated. In addition to the owner, in some
cases, other subjects involved in the organization of the site (staff
administrative, commercial, marketing, legal, system administrators) or external subjects
(such as third party technical service providers, couriers, hosting providers, IT companies,
communication agencies) also appointed, if necessary, Data Processors by the
Holder. The updated list of Managers can always be requested from the Data Controller
Legal basis of the processing
The Holder processes Personal Data relating to the User in the event one of the following conditions exists:
• the User has given consent for one or more specific purposes; Note: in some systems
the Data Controller can be authorized to process Personal Data without the existence of the
User's consent or another of the legal bases specified below, until
the User does not object ("opt-out") to this treatment. This however is not applicable if
the processing of Personal Data is regulated by European legislation on
protection of personal data;
• processing is necessary for the execution of a contract with the User and / or for the execution of
• processing is necessary to fulfill a legal obligation to which the Data Controller is subject;
• processing is necessary for the performance of a public interest task or for
the exercise of public powers with which the Data Controller is invested;
• the processing is necessary for the pursuit of the legitimate interest of the owner or third parties.
In any case, it is always possible to request the Data Controller to clarify the concrete legal basis of each
treatment and in particular to specify whether the treatment is based on the law, provided for by a
contract or necessary to conclude a contract.
The data are processed at the owner's operating offices and in any other place where the parties involved
in the treatment are localized.
For more information, contact the owner.
The User's Personal Data may be transferred to a country other than the one in which the User
is situated. To obtain further information on the place of treatment, the User can refer to
to the section on details on the processing of Personal Data.
The User has the right to obtain information regarding the legal basis for the transfer of Data to
outside the European Union or to an international international law organization
public or consisting of two or more countries, such as the UN, as well as on the measures of
security adopted by the Data Controller to protect the Data.
The User can check whether one of the transfers described above takes place by examining the section
of this document relating to details on the processing of Personal Data or request information from the
Owner by contacting him at the ends shown at the beginning.
The Data are processed and stored for the time required by the purposes for which they were collected.
• Personal Data collected for purposes related to the execution of a contract between the Owner and
the User will be held until the execution of this contract is completed.
• Personal Data collected for purposes related to the legitimate interest of the Owner will be
held until the satisfaction of this interest. The User can get further
information on the legitimate interest pursued by the Data Controller in the relevant sections of
this document or by contacting the owner.
When the treatment is based on the User's consent, the Data Controller can keep Personal Data
longer until such consent is revoked. In addition, the owner could be
obliged to keep Personal Data for a longer period in compliance with an obligation to
law or by order of an authority.
At the end of the retention period, Personal Data will be deleted. Therefore, at the expiration of
this term the right of access, cancellation, rectification and the right to data portability
they can no longer be exercised.
The use of the data collected
User data are collected to allow the owner to provide their services, as well as for
following purposes: Statistics, Interaction with external social networks and platforms, Access to
account on third party services and Contact the User.
To obtain further detailed information on the purposes of the processing and on Personal Data
concretely relevant for each purpose, the User can refer to the relevant sections of
Facebook permissions requested by la farmaveloce.com
Unless otherwise specified
The site may request some Facebook permissions that allow it to perform actions with the account
User's Facebook and to collect information, including Personal Data, from it. This service
allows the site to connect with the User's account on the Facebook social network, provided by
For more information on the following permissions, refer to the documentation of the
The required permits are as follows:
The basic information of the User registered on Facebook which normally includes the following
Data: id, name, image, gender and localization language and, in some cases, the "Friends" of
Facebook. If the User has made publicly available additional data, the same will be available.
Access to private data
Allows access to the User's and friends' private data.
Access to friend lists
Provides access to the lists of friends that the User has created.
Add or edit photos.
Allows the app to add or edit User videos.
Provides access to the list of events in which the User participates.
I like it
Provides access to the list of all the pages that the User has marked with the Like.
Provides access to the User's website.
Details on the processing of Personal Data
The Personal Data are collected for the following purposes and using the following services:
Access to accounts on third party services
This type of service allows the site to collect data from your accounts on third party services and
perform actions with them.
These services are not activated automatically, but require express authorization
Access to the Facebook account (farmaveloce.com)
This service allows the site to connect with the User's account on the social network
Facebook, provided by Facebook, Inc.
Permissions asked: Access to private data, Access to friend lists, Upload photos, Upload of
Videos, Events, Likes and Website.
Contact the user
By filling in the contact form with their Data, the User consents to their use for
respond to requests for information, quotes, or any other kind indicated
from the form header.
Personal data collected: post code, city, tax code, surname, address, country, name, number of
telephone, VAT number and various types of data.
Interaction with external social networks and platforms
This type of service allows you to interact with social networks, or with other platforms
external, directly from the pages of the site
The interactions and information acquired from the site are in any case subject to the settings
User privacy related to each social network.
In the event that an interaction service with social networks is installed, it is possible that, too
if Users do not use the service, it collects traffic data relating to the pages in
which it is installed on.
Like button and social widgets for Facebook (Facebook, Inc.)
The "Like" button and Facebook social widgets are social interaction services
Facebook network, provided by Facebook, Inc.
Personal Data collected: Cookies and Usage Data.
The services contained in this section allow the Data Controller to monitor and
analyze traffic data and are used to keep track of User behavior.
Google Analytics (Google Inc.)
Google Analytics is a web analysis service provided by Google Inc. ("Google"). Google uses i
Personal data collected for the purpose of tracking and examining the use of farmaveloce.com,
compile reports and share them with other services developed by Google.
Google may use the Personal Data to contextualise and personalize the advertisements of the
own advertising network.
Personal Data collected: Cookies and Usage Data.
More information on Personal Data
Selling goods and services online
The Personal Data collected is used for the provision of services to the User or for the sale of
products, including payment and possible delivery. Personal Data collected to perfect the
payment may be those relating to the credit card, the current account used for the
bank transfer or other expected payment instruments. Payment data collected by
farmaveloce.com depend on the payment system used.
Users may exercise certain rights with reference to the Data processed by the Data Controller.
In particular, the User has the right to:
• withdraw consent at any time. The User can withdraw consent to the treatment
of their Personal Data previously expressed.
• object to the processing of their data. The user can object to the processing of their data
when it occurs on a legal basis other than consent. Further details on the law
of opposition are indicated in the section below.
• access their Data. The User has the right to obtain information on the Data processed by the
Holder, on certain aspects of the treatment and to receive a copy of the Data processed.
• verify and request correction. The User can verify the correctness of their Data
and request its updating or correction.
• obtain the limitation of the treatment. When certain conditions are met,
the User can request the limitation of the processing of their Data. In this case the Owner
will not process the Data for any other purpose other than their conservation.
• obtain the cancellation or removal of their Personal Data. When they recur
certain conditions, the User can request the deletion of their Data by the
• receive your data or have it transferred to another holder. The User has the right to receive i
own Data in structured format, commonly used and readable by automatic device and, where
technically feasible, to obtain the transfer without hindrance to another owner. This
provision is applicable when the Data are processed with automated tools and the
processing is based on the User's consent, on a contract of which the User is a party or on
contractual measures connected to it.
• propose a complaint. The User can lodge a complaint with the supervisory authority of the
protection of personal data competent or to act in court.
Details on the right of opposition
When Personal Data are processed in the public interest, in the exercise of public powers referred to
the Owner is invested or to pursue a legitimate interest of the Owner, the Users have
right to object to processing for reasons related to their particular situation.
Users are reminded that if their data were processed for direct marketing purposes,
can oppose the treatment without giving any reason. To find out if the owner deals
data for direct marketing purposes Users can refer to the respective sections of
How to exercise the rights
To exercise the User's rights, Users can address a request to the ends of
contact of the Owner indicated in this document. Requests are filed free of charge and
processed by the Owner as soon as possible, in any case within a month.
Additional information on treatment
Defense in court
The User's Personal Data may be used by the Owner in court or in stages
preparatory to its possible establishment for the defense against abuse in the use of
farmaveloce.com or related Services by the User.
The User declares to be aware that the Data Controller may be obliged to reveal the Data
by order of the public authorities.
farmaveloce.com could provide the User with additional and contextual information
concerning specific Services, or the collection and processing of Personal Data.
Log System and Maintenance
For needs related to the operation and maintenance of the site and any third party services from
it used could collect system logs, that is files that record the interactions and that
they may also contain Personal Data, such as the User IP address.
Information not contained in this Policy
Further information in relation to the processing of Personal Data may be requested in
at any time to the Data Controller using the contact details.
Response to "Do Not Track" requests
The site does not support "Do Not Track" requests.
To find out if any third-party services used support them, the User is invited to
consult the respective privacy policies.
any time giving information to Users on this page and, if possible, on the site
as well as, if technically and legally feasible, by sending a notification to Users through one
of the contact details held by the Owner. Therefore, please consult regularly
this page, referring to the date of last modification indicated at the bottom.
If the changes affect treatments whose legal basis is consent, the Owner
will collect the User's consent again, if necessary.
Definitions and legal references
Personal Data (or Data)
It constitutes personal data any information that, directly or indirectly, also in
link with any other information, including an identification number
personal, makes a natural person identified or identifiable.
Data of Use
This is the information collected automatically through the site (also by party applications
third parties integrated into the site), including: IP addresses or domain names of the computers used
by the User who connects with the site, the addresses in URI (Uniform Resource Identifier) notation,
the time of the request, the method used to forward the request to the server, the file size
obtained in response, the numeric code indicating the status of the response from the server (successful, error,
etc.) the country of origin, the characteristics of the browser and operating system used by the
visitor, the various temporal connotations of the visit (for example the time spent on
each page) and the details of the itinerary followed within the Application, with
particular reference to the sequence of the pages consulted, to the parameters relating to the system
operating environment and the IT environment of the User.
The individual who uses the site which, unless otherwise specified, coincides with the interested party.
The natural person to whom the Personal Data refers.
Data Processor (or Manager)
The natural person, legal entity, public administration and any other entity that processes data
Data Controller (or Owner)
The natural or legal person, public authority, service or other body which, individually or
together with others, it determines the purposes and means of the processing of personal data and the tools
adopted, including the security measures relating to the operation and use of
farmaveloce.com. Unless otherwise specified, the Data Controller is the
owner of farmaveloce.com.
farmaveloce.com (or this Application)
The hardware or software tool through which the Personal Data of the
The service provided by the site as defined in the relative terms (if any) on this
site / application.
European Union (or EU)
Unless otherwise specified, any reference to the European Union contained in this
document is intended to be extended to all current member states of the European Union and Space
Small portion of data stored in the User's device.
This privacy statement is drawn up on the basis of multiple legislative systems, including articles 13 and 14 of the Regulation (EU) 2016 / 679.
Unless otherwise specified, this privacy statement only concerns the site.
RIGHT OF WITHDRAWAL
Deadline for withdrawal
The Consumer has a period of fourteen days to withdraw from the contract without having to provide any reason.
The aforementioned term starts:
a) if a service is offered from the day of the conclusion of the contract
b) in the case of sale of a product, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the goods or:
• in the case of multiple goods ordered by the Consumer through a single order and delivered separately, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last good;
• in the case of delivery of an asset consisting of lots or multiple pieces, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last lot or piece;
• in the case of contracts for the periodic delivery of goods during a certain period of time, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the first asset.
Obligations of the pharmacy The pharmacy, following the withdrawal of the consumer:
• immediately communicates to the Consumer a confirmation of receipt, on a durable medium, of the Withdrawal exercised;
• reimburses the same all payments received, not including delivery costs, without undue delay and in any case within fourteen days from the day of the communication of the Right of Withdrawal.
• the pharmacy reimburses using the same means of payment used by the Consumer, unless otherwise agreed after payment.
Obligations for the Consumer
The shipping costs for the return of the products received must be paid by the Consumer, which must be shipped within fourteen days from the date on which he communicated his decision to withdraw from the contract (the deadline is respected if the Consumer returns the goods before the expiry of the fourteen day period).
The substantial integrity of the asset is an essential condition for exercising the right of withdrawal. The Product must therefore be kept with normal diligence and returned intact, complete in all its parts, fully functional and free of signs of wear or dirt.
Exceptions to the Right of Withdrawal - products for which the application of the Right of Withdrawal is excluded
The right of withdrawal cannot be exercised:
a) in case of purchase of medicines and medical devices
b) supply of food, drinks or other goods intended for current consumption in the family and physically supplied by a professional in frequent and regular rounds to the consumer's home, residence or workplace
c) in the case of purchases of less than 50 euros (unless the total consideration that the Consumer must pay regardless of the amount of the individual contracts exceeds 50 euros);
d) in the case of a contract for a service after the complete provision of the service if the execution of the contract began with the express agreement of the Consumer;
e) in case of supply of goods made to measure or clearly personalized;
f) in the event of the supply of goods which are liable to deteriorate or expire rapidly;
g) in the case of the supply of sealed goods that do not lend themselves to be returned for reasons of hygiene or connected to the protection of health and have been opened after delivery;
h) in case of supply of goods which after delivery are by their nature inseparably mixed with other ben.
In the event of a lack of conformity, or delivery of goods that present defects or defects or are different from that provided in the sales contract, i.e. unsuitable for the use for which a good of the same is usually used
type, which differs from the description published on the site or which does not manifest the promised qualities, the provisions of the Legal Guarantee as per articles 128 and following of Legislative Decree 205/2006 (Consumer Code).
Any breakdowns or malfunctions caused by accidental events or by Customer's liability or by a use of the product not in accordance with its intended use and / or as foreseen in the technical documentation attached to the product are excluded from the scope of the Legal Guarantee.
The pharmacy is liable when the lack of conformity occurs within two years from the delivery of the goods, unless there is a conventional guarantee beyond this term. In case of sale of used goods, the guarantee referred to in the previous paragraph may be limited to a period of time however
not less than one year.
The Consumer is required to report the defect or defect to me quickly within two months of discovery (unless the sector has recognized or concealed the existence of the defect).
It is assumed that the defects of conformity that occur within six months of delivery of the goods already existed on that date, unless this hypothesis is incompatible with the nature of the asset or with the nature of the defect of
The direct action to assert defects not maliciously concealed by the seller is prescribed within twenty-six months from the delivery of the goods (the Consumer who is agreed for the execution of the contract can nevertheless always assert the rights referred to in this article provided that the lack of conformity has been reported within two months of discovery and before the expiry of the two years from delivery).
In the event of a lack of conformity, the Consumer can request, at no cost (including shipping), the restoration by repair or replacement, at his choice, unless the remedy is objectively impossible or excessively expensive compared to the other.
The above remedy is to be considered excessively expensive if it imposes unreasonable costs on the store compared to the other, taking into account:
a) the value that the asset would have if there were no lack of conformity;
b) the extent of the lack of conformity;
c) the possibility that the alternative remedy can be tried without significant inconvenience for the Consumer.
Repairs or replacements will be carried out within a reasonable time from the request and must not cause significant inconvenience to the Consumer, taking into account the nature of the goods and the purpose for which it was purchased.
The Consumer can request, at his choice, a reasonable reduction in the price or termination of the contract if one of the following situations occurs:
a) repair and replacement are impossible or excessively expensive;
b) the seller did not replace within a reasonable time;
c) the replacement or repair previously carried out has caused significant inconvenience to the Consumer.
The use of the asset is taken into account when determining the amount of the reduction or the amount to be returned.
After reporting the lack of conformity, the seller can offer the consumer any other available remedy, with the following effects:
a) if the Consumer has already requested a specific remedy, the seller remains obliged to implement it, with the necessary consequences regarding the commencement of the appropriate term for repairs or replacements, unless the Consumer accepts the proposed alternative remedy;
b) if the Consumer has not already requested a specific remedy, the Consumer must accept the proposal or reject it by choosing another remedy pursuant to this article.
A slight lack of conformity, for which it has not been possible or is excessively burdensome to carry out the remedies of repair or replacement, does not give the right to terminate the contract.
The Legal Guarantee is limited to purchases made by Consumers. As regards subjects other than Consumers, the provisions of the Consumer Code apply to Articles 1490 et seq.
Conventional Manufacturer Warranty
The products sold on the Site may, depending on their nature, be covered by a conventional warranty issued by the manufacturer ("Conventional Warranty"). The customer can only enforce this guarantee against the manufacturer. The duration, the extension, also territorial, the conditions and methods of use, the types of damage / defects covered and any limitations of the Conventional Warranty depend on the individual manufacturer and are indicated in the so-called warranty certificate contained in the product packaging. The Conventional Guarantee is voluntary in nature and does not add, replace, limit or prejudice or exclude the Legal Guarantee.
Payment and security
Your payment information is processed securely. We do not store credit card details nor do we have access to your credit card information.
Lactoferrin 200 Mg Immuno 30 Stickpack
LATTOFERRINA 200 IMMUNO is a food supplement of lactoferrin. Lactoferrin is a multifunctional protein with antimicrobial and antiviral properties